Current Landscape of NTRK Inhibition for Pediatric CNS Tumors

2024-9-15

Rett Syndrome: The Emerging Landscape of Treatment Strategies

2024-9-9

Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study

2024-9-6

Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

2024-8-30

Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies

2024-8-22

Glutamatergic Modulators for Major Depression from Theory to Clinical Use

2024-8-16

Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis

2024-8-9

New and Emerging Drug and Gene Therapies for Friedreich Ataxia

2024-8-8

Antiseizure Medications and Sudden Unexpected Death in Epilepsy: An Updated Review

2024-8-7

Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study

2024-8-3

Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases

2024-8-3

Incident Benzodiazepine and Z-Drug Use and Subsequent Risk of Serious Infections

2024-8-1

Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database

2024-7-26

Psychotropic Drugs Reemerging as Headache Medicines

2024-7-22

Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges

2024-7-20

Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

2024-7-11

A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial

2024-7-2

The State of Synthetic Cannabinoid Medications for the Treatment of Pain

2024-7-1

When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis

2024-7-1

Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development

2024-6-27

The Use of Ketamine for the Treatment of Anhedonia in Depression

2024-6-23

A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease

2024-6-5

Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics

2024-6-5

Targeting Biometals in Alzheimer’s Disease with Metal Chelating Agents Including Coumarin Derivatives

2024-6-3

Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy

2024-5-31

Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population

2024-5-29

Sex Differences in the Dual Antiplatelet Therapy Versus Alteplase for Patients with Minor Nondisabling Acute Ischemic Stroke: A Secondary Analysis of the ARAMIS Study

2024-5-28

FcRn Inhibitor Therapies in Neurologic Diseases

2024-5-9

Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia

2024-5-7

Sex Differences in Adverse Effects of Antiseizure Medications in Adults with Epilepsy: A Systematic Review

2024-4-30

Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety

2024-4-24

Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data

2024-4-18

Ticagrelor Versus Clopidogrel in Acute Large-Vessel Ischemic Stroke: A Randomized Controlled Single-Blinded Trial

2024-4-15

Impulse Control Disorders in Parkinson’s Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management

2024-4-13

Oral Delta-9-Tetrahydrocannabinol (THC) Increases Parasympathetic Activity and Supraspinal Conditioned Pain Modulation in Chronic Neuropathic Pain Male Patients: A Crossover, Double-Blind, Placebo-Controlled Trial

2024-4-10

On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis

2024-4-8

Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

2024-4-7

CNS Viral Infections—What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches

2024-4-5

Observation on the Analgesic Effect of Different Doses of a Combination of Esketamine and Dexmedetomidine Administered for Percutaneous Endoscopic Transforaminal Discectomy: A Randomized, Double-Blind Controlled Trial

2024-4-4

The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications

2024-4-3

The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations

2024-3-23

An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders

2024-3-19

Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis

2024-3-15

Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period

2024-3-15

Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options

2024-3-14

Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis

2024-3-1

The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study

2024-2-29

Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis

2024-2-29

Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study

2024-2-28

SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants

2024-2-28